The SURMOUNT-1 trial (tirzepatide, published in NEJM 2022) demonstrated that participants with obesity or overweight without diabetes who received tirzepatide experienced weight reductions of 16.0% ...

Following Oral Wegovy Introduction, Consumer Analysis Examines Injectable vs Oral Semaglutide Pricing, Compounded Tirzepatide Access Through Direct Meds, and Three-Entity Telehealth Platform ...

Semaglutide 2.4 mg could prevent nearly 2 million major cardiac events and over 1 million deaths in eligible patients. Uptake of semaglutide remains low due to cost, supply issues, and payer approval ...

Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 ...

Obesity and type 2 diabetes are prevalent in patients with heart failure with preserved ejection fraction and are characterized by a high symptom burden. No approved therapies specifically target ...